Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Sirolimus (Oncology Use) |
mTOR Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Sirolimus (Oncology Use)
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
mTOR Inhibitor |
||||
Sitravatinib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Sitravatinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Sonidegib |
Hedgehog Pathway Inhibitor | Solid Tumour / Hematologic (AML) | ||
|
Molecule
Sonidegib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour / Hematologic (AML)
Drug Class / Mechanism
Hedgehog Pathway Inhibitor |
||||
Sonrotoclax |
BCL-2 Inhibitor | Hematologic | ||
|
Molecule
Sonrotoclax
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
BCL-2 Inhibitor |
||||
Sorafenib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Sorafenib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Sorafenib (AML use) |
FLT3 Inhibitor | Hematologic (AML) | ||
|
Molecule
Sorafenib (AML use)
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
||||
Sotorasib |
RET / MET / KRAS / IDH Inhibitor | Solid Tumour | ||
|
Molecule
Sotorasib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
||||
Spebrutinib |
BTK Inhibitor | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Spebrutinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
||||
Stenoparib |
PARP Inhibitor | Solid Tumour | ||
|
Molecule
Stenoparib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
PARP Inhibitor |
||||
Strontium-89 Chloride |
Radiotherapeutic / Radiodiagnostic Agent | Both (Solid & Hematologic) | ||
|
Molecule
Strontium-89 Chloride
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
||||
Sunitinib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Sunitinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Sunvozertinib |
EGFR / HER2 Tyrosine Kinase Inhibitor | Solid Tumour | ||
|
Molecule
Sunvozertinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
||||
Sirolimus (Oncology Use)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
mTOR Inhibitor |
|
SitravatinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
SonidegibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour / Hematologic (AML)
Drug Class / Mechanism
Hedgehog Pathway Inhibitor |
|
SonrotoclaxTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
BCL-2 Inhibitor |
|
SorafenibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
Sorafenib (AML use)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
|
SotorasibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
|
SpebrutinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
|
StenoparibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
PARP Inhibitor |
|
Strontium-89 ChlorideRadiopharmaceutical / Nuclear Medicine |
|
|
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
|
SunitinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
SunvozertinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
|